GALECTIN THERAPEUTICS INC — Quarterly Financials
Quarterly figures from SEC EDGAR XBRL filings (10-Q)
These figures are extracted from XBRL-tagged quarterly reports (10-Q) that GALECTIN THERAPEUTICS INC filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.
Net Income — By Quarter
| Quarter | Fiscal Year | Period End | Value | Filed |
|---|---|---|---|---|
| Q3 | 2025 | Sep 30, 2025 | ($8.18M) | Nov 14, 2025 |
| Q2 | 2025 | Jun 30, 2025 | ($7.52M) | Aug 14, 2025 |
| Q1 | 2025 | Mar 31, 2025 | ($9.63M) | May 15, 2025 |
| Q3 | 2025 | Sep 30, 2024 | ($11.22M) | Nov 14, 2025 |
| Q2 | 2025 | Jun 30, 2024 | ($12.37M) | Aug 14, 2025 |
| Q1 | 2025 | Mar 31, 2024 | ($11.49M) | May 15, 2025 |
| Q3 | 2024 | Sep 30, 2023 | ($10.43M) | Nov 14, 2024 |
| Q2 | 2024 | Jun 30, 2023 | ($9.11M) | Aug 13, 2024 |
| Q1 | 2024 | Mar 31, 2023 | ($11.53M) | May 15, 2024 |
| Q3 | 2023 | Sep 30, 2022 | ($8.60M) | Nov 13, 2023 |
| Q2 | 2023 | Jun 30, 2022 | ($9.61M) | Aug 14, 2023 |
| Q1 | 2023 | Mar 31, 2022 | ($9.93M) | May 15, 2023 |
| Q3 | 2022 | Sep 30, 2021 | ($8.52M) | Nov 14, 2022 |
| Q2 | 2022 | Jun 30, 2021 | ($8.45M) | Aug 15, 2022 |
| Q1 | 2022 | Mar 31, 2021 | ($6.34M) | May 16, 2022 |
| Q3 | 2021 | Sep 30, 2020 | ($5.94M) | Nov 15, 2021 |
| Q2 | 2021 | Jun 30, 2020 | ($6.11M) | Aug 16, 2021 |
| Q1 | 2021 | Mar 31, 2020 | ($3.56M) | May 17, 2021 |
| Q3 | 2020 | Sep 30, 2019 | ($2.78M) | Nov 9, 2020 |
| Q2 | 2020 | Jun 30, 2019 | ($3.00M) | Aug 10, 2020 |
Operating Income — By Quarter
| Quarter | Fiscal Year | Period End | Value | Filed |
|---|---|---|---|---|
| Q3 | 2025 | Sep 30, 2025 | ($4.20M) | Nov 14, 2025 |
| Q2 | 2025 | Jun 30, 2025 | ($4.63M) | Aug 14, 2025 |
| Q1 | 2025 | Mar 31, 2025 | ($7.90M) | May 15, 2025 |
| Q3 | 2025 | Sep 30, 2024 | ($9.07M) | Nov 14, 2025 |
| Q2 | 2025 | Jun 30, 2024 | ($11.29M) | Aug 14, 2025 |
| Q1 | 2025 | Mar 31, 2024 | ($9.65M) | May 15, 2025 |
| Q3 | 2024 | Sep 30, 2023 | ($9.17M) | Nov 14, 2024 |
| Q2 | 2024 | Jun 30, 2023 | ($9.00M) | Aug 13, 2024 |
| Q1 | 2024 | Mar 31, 2023 | ($10.34M) | May 15, 2024 |
| Q3 | 2023 | Sep 30, 2022 | ($8.12M) | Nov 13, 2023 |
| Q2 | 2023 | Jun 30, 2022 | ($9.66M) | Aug 14, 2023 |
| Q1 | 2023 | Mar 31, 2022 | ($9.94M) | May 15, 2023 |
| Q3 | 2022 | Sep 30, 2021 | ($8.24M) | Nov 14, 2022 |
| Q2 | 2022 | Jun 30, 2021 | ($8.19M) | Aug 15, 2022 |
| Q1 | 2022 | Mar 31, 2021 | ($6.32M) | May 16, 2022 |
| Q3 | 2021 | Sep 30, 2020 | ($5.93M) | Nov 15, 2021 |
| Q2 | 2021 | Jun 30, 2020 | ($6.10M) | Aug 16, 2021 |
| Q1 | 2021 | Mar 31, 2020 | ($3.58M) | May 17, 2021 |
| Q3 | 2020 | Sep 30, 2019 | ($2.86M) | Nov 9, 2020 |
| Q2 | 2020 | Jun 30, 2019 | ($3.02M) | Aug 10, 2020 |